Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
46.09 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 644.395 | 498.987 | 437.768 | 349.846 | 322.357 | 294.666 | 240.175 | 255.165 | 251.519 | 210.461 | 229.681 | 204.323 | 118.356 |
| Cost of Revenue
| 300.427 | 250.127 | 238.029 | 206.506 | 190.434 | 187.681 | 149.38 | 150.976 | 174.172 | 159.205 | 142.725 | 114.02 | 90.252 |
| Gross Profit
| 343.968 | 248.86 | 199.739 | 143.34 | 131.923 | 106.985 | 90.795 | 104.189 | 77.347 | 51.256 | 86.956 | 90.303 | 28.104 |
| Gross Profit Ratio
| 0.534 | 0.499 | 0.456 | 0.41 | 0.409 | 0.363 | 0.378 | 0.408 | 0.308 | 0.244 | 0.379 | 0.442 | 0.237 |
| Reseach & Development Expenses
| 63.888 | 74.771 | 60.932 | 67.229 | 68.853 | 57.564 | 43.415 | 41.199 | 37.065 | 28.427 | 33.019 | 31.163 | 31.049 |
| General & Administrative Expenses
| 51.54 | 45.061 | 51.434 | 50.377 | 50.279 | 49.888 | 44.458 | 41.832 | 41.504 | 34.809 | 30.972 | 27.223 | 26.433 |
| Selling & Marketing Expenses
| 28.853 | 21.531 | 17.486 | 14.78 | 12.83 | 8.156 | 6.46 | 5.466 | 5.47 | 5.564 | 5.349 | 4.426 | 4.1 |
| SG&A
| 80.393 | 66.592 | 68.92 | 65.157 | 63.109 | 58.044 | 50.918 | 47.298 | 46.974 | 40.373 | 36.321 | 31.649 | 30.533 |
| Other Expenses
| -3.929 | 8.543 | 14.252 | -6.317 | 60.267 | -1.303 | 2.518 | -0.746 | -2.794 | -0.165 | 0.508 | 1.023 | 1.841 |
| Operating Expenses
| 144.281 | 141.363 | 129.852 | 132.386 | 131.962 | 115.608 | 94.333 | 88.497 | 84.039 | 68.8 | 69.34 | 62.812 | 61.582 |
| Operating Income
| 199.687 | 78.756 | 43.135 | -14.226 | -0.039 | -8.623 | -0.895 | 15.692 | -6.898 | -17.983 | 17.49 | 25.397 | -33.545 |
| Operating Income Ratio
| 0.31 | 0.158 | 0.099 | -0.041 | -0 | -0.029 | -0.004 | 0.061 | -0.027 | -0.085 | 0.076 | 0.124 | -0.283 |
| Total Other Income Expenses Net
| -28.328 | 37.284 | 41.004 | 18.863 | 60.267 | -1.303 | 5.161 | -0.746 | -3 | -0.604 | 0.382 | -1.071 | 1.774 |
| Income Before Tax
| 171.359 | 116.04 | 84.139 | 4.637 | 60.228 | -9.926 | 1.623 | 14.946 | -10.364 | -18.148 | 17.227 | 25.878 | -31.887 |
| Income Before Tax Ratio
| 0.266 | 0.233 | 0.192 | 0.013 | 0.187 | -0.034 | 0.007 | 0.059 | -0.041 | -0.086 | 0.075 | 0.127 | -0.269 |
| Income Tax Expense
| 31.833 | 23.477 | 20.63 | 3.54 | 13.723 | -3.266 | -2.885 | 4.414 | -7.577 | -7.449 | 5.365 | 7.784 | -39.639 |
| Net Income
| 137.545 | 91.386 | 62.116 | 1.097 | 48.939 | -5.738 | 4.508 | 10.532 | -2.787 | -10.699 | 11.862 | 18.094 | 7.752 |
| Net Income Ratio
| 0.213 | 0.183 | 0.142 | 0.003 | 0.152 | -0.019 | 0.019 | 0.041 | -0.011 | -0.051 | 0.052 | 0.089 | 0.065 |
| EPS
| 2.85 | 1.88 | 1.3 | 0.023 | 1.04 | -0.12 | 0.1 | 0.23 | -0.062 | -0.25 | 1.48 | 2.26 | 0.97 |
| EPS Diluted
| 2.6 | 1.74 | 1.25 | 0.022 | 0.98 | -0.12 | 0.09 | 0.22 | -0.062 | -0.25 | 1.48 | 2.26 | 0.97 |
| EBITDA
| 241.464 | 107.497 | 69.887 | 10.954 | -0.039 | -8.623 | -6.181 | 15.692 | 4.081 | -17.105 | 31.389 | 40.253 | -20.086 |
| EBITDA Ratio
| 0.375 | 0.215 | 0.16 | 0.031 | -0 | -0.029 | -0.026 | 0.061 | 0.016 | -0.081 | 0.137 | 0.197 | -0.17 |